Hibvaccin

Hibvaccin is a vaccine designed to prevent infections caused by Haemophilus influenzae type b (Hib). Haemophilus influenzae type b is a bacterium that can cause serious and potentially life-threatening illnesses, particularly in young children. These illnesses can include meningitis, epiglottitis, pneumonia, and bacteremia. Before the widespread use of the Hib vaccine, Hib was a leading cause of bacterial meningitis in children under five years old.

The Hib vaccine is typically administered in a series of doses, usually starting in infancy. The recommended schedule can vary slightly by country and health organization, but it commonly involves primary doses at two, four, and six months of age, followed by a booster dose between twelve and fifteen months. The vaccine works by stimulating the immune system to produce antibodies against the Hib bacterium, providing protection against invasive disease.

The Hib vaccine is highly effective and has significantly reduced the incidence of Hib disease worldwide. Its introduction is considered one of the major public health successes of the late 20th century. The vaccine is generally safe, with common side effects being mild and temporary, such as soreness at the injection site, fever, or fussiness. Serious side effects are very rare. Hib vaccination is a routine part of childhood immunization programs in most developed countries.